Browse by author
Lookup NU author(s): Professor Anthony De SoyzaORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
BACKGROUND: Comorbid rheumatoid arthritis (RA) is known to be associated with excess mortality in patients with bronchiectasis. However, whether excess mortality is affected by RA seropositivity and is altered by using disease-modifying anti-rheumatic drugs (DMARDs) remains unknown. OBJECTIVES: To assess the association between comorbid RA and mortality in participants with bronchiectasis, plus the impacts of seropositivity and DMARDs on this association. DESIGN: A retrospective cohort study. METHODS: Mortality rates were compared between participants with bronchiectasis-RA overlap syndrome (BROS) (n = 3355; 2632 seropositive RA (SPRA) and 723 seronegative RA (SNRA)) and 1:5 age- and sex-matched participants with bronchiectasis only (n = 16,240) who were enrolled between 2010 and 2017 in the Korean National Health Insurance Service database. The participants were followed up from 1 year after RA diagnosis or the corresponding index date to the date of death, censored date, or 31 December 2020. RESULTS: During a median follow-up of 5.8 years (interquartile range, 4.2-7.8 years), participants with BROS revealed a 2.09-fold higher mortality risk compared with participants with bronchiectasis only, even after adjusting for potential confounders (95% confidence interval (CI), 1.88-2.33). In an analysis of RA serologic status using a fully adjusted model, participants with SPRA and those with SNRA showed 2.34-fold (95% CI, 2.09-2.62) and 1.29-fold (95% CI, 1.01-1.65) increased risks, respectively, than participants with bronchiectasis only. DMARDs use was related to increased mortality. CONCLUSION: The presence of RA doubles the mortality risk in patients with bronchiectasis. Increased mortality risk was more evident in patients with SPRA and those who use DMARDs. Causality cannot be ascertained, but these data suggest that rheumatic inflammation may affect disease progression and excess mortality in patients with BROS.
Author(s): Choi H, Han K, Jung JH, De Soyza A, Kim H, Shin DW, Lee H
Publication type: Article
Publication status: Published
Journal: Therapeutic Advances in Respiratory Disease
Year: 2025
Volume: 19
Pages: 1-13
Online publication date: 05/08/2025
Acceptance date: 02/07/2025
Date deposited: 26/08/2025
ISSN (print): 1753-4666
ISSN (electronic): 1753-4666
Publisher: Sage Publications
URL: https://doi.org/10.1177/17534666251360071
DOI: 10.1177/17534666251360071
Data Access Statement: The datasets used and/or analysed during the current study are available from the corresponding authors upon reasonable request.
PubMed id: 40765176
Altmetrics provided by Altmetric
